Daily News
Daily News

CCL-11 or eotaxin-1: an Immune marker for aging and accelerated aging in neuro-psychiatric disorders

Mental Health News Daily

2020 SEP 18 (NewsRx) -- By a News Reporter-Staff News Editor at Mental Health News Daily -- Data detailed on schizophrenia have been presented. According to news originating from Plovdiv, Bulgaria, by NewsRx correspondents, research stated, “CCL-11 (eotaxin) is a chemokine with an important role in allergic conditions. Recent evidence indicates that CCL-11 plays a role in brain disorders as well.”

The news journalists obtained a quote from the research from Medical University-Plovdiv: “This paper reviews the associations between CCL-11 and aging, neurodegenerative, neuroinflammatory and neuropsychiatric disorders. Electronic databases were searched for original articles examining CCL-11 in neuropsychiatric disorders. CCL-11 is rapidly transported from the blood to the brain through the blood-brain barrier. Age-related increases in CCL-11 are associated with cognitive impairments in executive functions and episodic and semantic memory, and therefore, this chemokine has been described as an ‘Endogenous Cognition Deteriorating Chemokine’ (ECDC) or ‘Accelerated Brain-Aging Chemokine’ (ABAC). In schizophrenia, increased CCL-11 is not only associated with impairments in cognitive functions, but also with key symptoms including formal thought disorders. Some patients with mood disorders and premenstrual syndrome show increased plasma CCL-11 levels. In diseases of old age, CCL-11 is associated with lowered neurogenesis and neurodegenerative processes, and as a consequence, increased CCL-11 increases risk towards Alzheimer’s disease. Polymorphisms in the CCL-11 gene are associated with stroke. Increased CCL-11 also plays a role in neuroinflammatory disease including multiple sclerosis. In animal models, neutralization of CCL-11 may protect against nigrostriatal neurodegeneration. Increased production of CCL-11 may be attenuated by glucocorticoids, minocycline, resveratrol and anti-CCL11 antibodies.”

According to the news reporters, the research concluded: “Increased CCL-11 production during inflammatory conditions may play a role in human disease including age-related cognitive decline, schizophrenia, mood disorders and neurodegenerative disorders. Increased CCL-11 production is a new drug target in the treatment and prevention of those disorders.”

For more information on this research see: CCL-11 or Eotaxin-1: An Immune Marker for Ageing and Accelerated Ageing in Neuro-Psychiatric Disorders. Pharmaceuticals, 2020,13(230):230. (Pharmaceuticals - http://www.mdpi.com/journal/pharmaceuticals/). The publisher for Pharmaceuticals is MDPI AG.

A free version of this journal article is available at https://doi.org/10.3390/ph13090230.

Our news editors report that additional information may be obtained by contacting Mariya Ivanovska, Department of Microbiology and Immunology, Faculty of Pharmacy, Research Institute, Medical University-Plovdiv, 4002 Plovdiv, Bulgaria. Additional authors for this research include Zakee Abdi, Marianna Murdjeva, Danielle Macedo, Annabel Maes, Michael Maes.

(Our reports deliver fact-based news of research and discoveries from around the world.)